Fundraisings and IPOs

* On October 13, 2014, Nanobiotix  announced the second payment of 1.144 k€ from Bpifrance as part as the funding granted to support the NICE consortium.Taking into account the development of the Strategic Industrial Innovation (ISI) program and based on the completion of the first milestone “Etape clé 1”, Bpifrance has proceed to transfer 1.144 k€ to Nanobiotix. In January 2014, Nanobiotix has received an initial payment of 461 k€ from Bpifrance. Nanobiotix pursued the non-clinical evaluation phase of NBTXR3 with a view to initiating a clinical trial of NBTXR3 in patients suffering from liver cancer. In this population of patients, the aim of using the product is to increase and prolong patients’ survival. This non-clinical evaluation phase should allow Nanobiotix to initiate the clinical development in these cancer diseases in 2015.

* On July 3, 2013, Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has announced that it has secured €9 million in funding from bpifrance (formerly OSEO) of which €2.8 million is directly attributable to the Company. This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma).

This grant supports the launch of NICE (Nano Innovation for CancEr), the first consortium of nanomedicine stakeholders in France focused on characterization and industrialization aspects. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France. The NICE consortium consists of five public and private partners. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner. In addition to Nanobiotix, the consortium includes BioAlliance Pharma, developer of Livatag®, a doxorubicin nanoparticle currently in phase III trial for the treatment of primary liver cancer; CEA-Leti, developer of the Lipidots® platform that uses lipid nanoparticles; DBI, a company specializing in the production of nanomedicine pharmaceutical products and Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specializing in nanoparticle research..

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for advanced soft tissue sarcoma and has received authorization from the French Medicine Agency, ANSM, to start a second clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer). NBTXR3 will benefit fully from this platform of expertise and funding received from bpifrance by being able to accelerate its clinical development. The purpose of this project is the start of a new Phase I clinical study with NBTXR3 in patients with primary liver cancer.